NONALCOHOLIC STEATOHEPATITIS
Clinical trials for NONALCOHOLIC STEATOHEPATITIS explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New NASH drug shows promise in early trial
Disease control CompletedThis study tested an experimental drug called HPG1860 in 89 adults with NASH, a serious liver disease linked to obesity. Participants received one of three doses of the drug or a placebo for 12 weeks. The main goals were to check safety and see if the drug could reduce liver fat.…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: Hepagene (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 12, 2026 12:03 UTC
-
New shot targets fatty liver disease in genetically At-Risk patients
Disease control CompletedThis study tested a drug called AZD2693 in 220 adults with a type of fatty liver disease (NASH) and liver scarring, but not cirrhosis. All participants had a specific gene variant (PNPLA3 148M) that raises their risk. The goal was to see if the drug could improve liver health by …
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Massive study tracks fatty liver disease patients to uncover Real-World treatment patterns
Knowledge-focused CompletedThis study followed over 7,300 people with nonalcoholic fatty liver disease (NAFLD) and its more severe form, NASH, in regular doctor visits. Researchers aimed to understand how the disease progresses and what treatments doctors are using, since no drugs are officially approved f…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS
Sponsor: Target PharmaSolutions, Inc. • Aim: Knowledge-focused
Last updated Jun 17, 2026 03:43 UTC